TY  - BOOK
AU  - Evan, Jennifer R
TI  - Alemtuzumab for the treatment of multiple sclerosis
SN  - 1471-2598
PY  - 2018///
KW  - *Alemtuzumab/tu [Therapeutic Use]
KW  - *Multiple Sclerosis, Relapsing-Remitting/dt [Drug Therapy]
KW  - Alemtuzumab/ae [Adverse Effects]
KW  - Alemtuzumab/pk [Pharmacokinetics]
KW  - CD52 Antigen/im [Immunology]
KW  - Clinical Trials as Topic
KW  - Half-Life
KW  - Humans
KW  - Magnetic Resonance Imaging
KW  - Multiple Sclerosis, Relapsing-Remitting/dg [Diagnostic Imaging]
KW  - Multiple Sclerosis, Relapsing-Remitting/pa [Pathology]
KW  - Natalizumab/pk [Pharmacokinetics]
KW  - Natalizumab/tu [Therapeutic Use]
KW  - Product Surveillance, Postmarketing
KW  - Treatment Outcome
KW  - MedStar Union Memorial Hospital
KW  - Journal Article
N2  - Introduction Alemtuzumab is a monoclonal antibody that targets for the destruction CD52+ cells, particularly B and T cells. Alemtuzumab is approved in more than 50 countries around the world for the treatment of adult patients with relapsing remitting multiple sclerosis (MS). Areas covered In this review, the authors summarize biological, clinical and safety data related to the use of alemtuzumab in patients with MS. The authors then provide their expert opinion on alemtuzumab and the field as of whole before providing their perspectives for the future. Expert opinion Alemtuzumab is highly efficacious; more so than first line treatments but comparable to natalizumab. Treatment schedule makes alemtuzumab administration easy and attractive to patients. However, its safety profile makes it a choice for a very limited number of patients, in a specific disease window. As of now, a cure for MS remains elusive and there is an unmet need for a safe and highly potent agent at the level of and beyond the blood brain barrier
UR  - https://dx.doi.org/10.1080/14712598.2018.1425388
ER  -